Contact Us About Medicines Science Our Purpose News Investors Careers Home About Jazz > History HISTORY About Jazz Leadership Board of Directors Global Footprint History Corporate Values Corporate Development Partnering Manufacturing Villa Guardia, Italy (Gentium S.r.l) Athlone, Ireland (Jazz Pharmaceuticals Ireland Limited) When I co-founded Jazz Pharmaceuticals, our vision was to create a company with a constant focus on patients and a commitment to being a great place to work.” Bruce Cozadd, Chairman and CEO History Acquired GW Pharmaceuticals in 2Q21 2021 2020 European rolling launch of Sunosi® U.S. launch of Zepzelca™ Xywav™ U.S. approval Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies Acquired worldwide rights to SpringWorks Therapeutics’ FAAH Inhibitor Program Acquired pre-clinical Pan-RAF inhibitor program from Redx Pharma U.S. Launch of Sunosi® Entered into strategic collaboration with Codiak BioSciences Acquired Cavion, including worldwide rights to JZP-385 Acquired rights to lurbinectedin in the U.S. from PharmaMar 2019 2018 FDA approval of Xyrem for an additional patient population European rolling launch of Vyxeos® Entered into strategic collaboration with MD Anderson Entered into strategic collaboration with ImmunoGen U.S. Launch of Vyxeos® 2017 2016 Opened new manufacturing facility in Athlone, Ireland and received a Facility of the Year Award in 2017 from the International Society for Pharmaceutical Engineering (ISPE) for Best Project Execution Acquired Celator Pharmaceuticals, which added Vyxeos® U.S. launch of Defitelio® Initiation of JZP-110 Phase 3 clinical program 2015 2014 Acquired rights to defibrotide in the Americas from Sigma-Tau Pharma Acquired Gentium, which added Defitelio® (defibrotide) to our product portfolio; European commercial launch of Defitelio Acquired rights to JZP-110 from Aerial BioPharma Acquired EUSA Pharma, which extended our product offerings to include Erwinaze®/ Erwinase®, and helped us establish our European commercial infrastructure Merger with Azur Pharma, which provided a new global headquarters in Dublin, Ireland, bringing in new employees and new members of our management team 2012 2005 Acquired Orphan Medical and its product, Xyrem® Management team assembled/capital raised 2004 2003 Jazz Pharmaceuticals founded About Leadership Board of Directors Global Footprint History Corporate Values Corporate Development Manufacturing News Our Stories Careers Medicines Our Medicines Drug Safety Medical Information US Medical Information Outside of the US Science Pipeline Clinical Trials Expanded Access Independent Scientific Research Our Purpose Patient Assistance Corporate Giving Patient Resources Environmental, Social, Governance and Disclosures Ethical Standards Medical Education Transfers of Value in Europe Investors Events / Presentations Stock Information SEC Filings GAAP To Non-GAAP Reconciliations Annual Reports Quarterly Results Analyst Coverage Information Request FAQs Other Information l © 2021 Jazz Pharmaceuticals, Inc. All Rights Reserved. Privacy Statement Terms of Use Social Media Global Guidelines Cookie Policy Sitemap